Prostate Cancer Active Surveillance: Quality Matters

Author:
Peter J. Van Veldhuizen
Search for other papers by Peter J. Van Veldhuizen in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Disclosures: The author has disclosed not having any financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Peter J. Van Veldhuizen, MD, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642. Email: Peter_vanveldhuizen@urmc.rochester.edu

View associated content

  • Collapse
  • Expand
  • 1.

    Burgess L, Aldrighetti CM, Ghosh A, et al. Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality. JAMA Netw Open 2022;5:e2211869.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Timilshina N, Finelli A, Tomlinson G, et al. Applying quality indicators to examine quality of care during active surveillance in low-risk prostate cancer: a population-based study. J Natl Compr Canc Netw 2023;21:465472.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Fastenau J, Jain K, Popovic A, Kovac E. Review of active surveillance in underrepresented and high-risk populations: feasibility and safety. Curr Urol Rep. Published online March 31, 2023. doi: 10.1007/s11934-023-01158-5

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Schneider AC, Chandrasekar T, Bowler N, et al. Impact of an expanded definition of family history on outcomes of active surveillance for prostate cancer. J Urol. Published online March 24, 2023. doi: 10.1097/ju.0000000000003396

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Ordner J, Flaifel A, Serrano A, et al. Significance of the percentage of Gleason pattern 4 at prostate biopsy in predicting adverse pathology on radical prostatectomy: application in active surveillance. Am J Clin Pathol. Published online March 11, 2023. doi: 10.1093/ajcp/aqad005

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Courtney PT, Deka R, Kotha NV, et al. Metastasis and mortality in men with low- and intermediate-risk prostate cancer on active surveillance. J Natl Compr Canc Netw 2022;20:151159.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lokeshwar SD, Syed JS, Segal D, et al. Optimal use of tumor-based molecular assays for localized prostate cancer. Curr Oncol Rep 2022;24:249256.

  • 8.

    Chamorro Castillo L, García Morales L, Ruiz López D, et al. The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice. Prostate. Published online March 11, 2023. doi: 10.1002/pros.24515

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Moore CM, King LE, Withington J, et al. Best current practice and research priorities in active surveillance for prostate cancer:-a report of a Movember International Consensus Meeting. Eur Urol Oncol 2023;6:160182.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Oerther B, Engel H, Nedelcu A, et al. Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: performance of a fully automated AI-algorithm for lesion detection and classification. Prostate. Published online March 25, 2023. doi: 10.1002/pros.24528

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1924 796 20
PDF Downloads 1458 532 15
EPUB Downloads 0 0 0